GET DAILY SIGNALSWhy Is Twist Bioscience (TWST) Stock Down -15.22% Today?
Key Takeaways
- TWST shares fell about 15.22% to $103.93 after closing the prior session at $122.59.
- The drop came despite a fiscal fourth-quarter earnings beat, as investors focused on lighter-than-hoped fiscal 2027 guidance.
- Gross margin and AI drug discovery growth outlooks trailed elevated expectations after the stock's sharp year-to-date rally.
- A recent short-seller report, high short interest, and insider selling weighed on sentiment ahead of the print.
- Broader weakness in high-beta growth and genomics names amplified the selloff.
- Traders are watching analyst revisions, upcoming guidance commentary, and whether the stock can hold key technical levels.
- For more context, explore Price Targets, Earnings, and Forecast pages for TWST.
- Discover actionable trading ideas on Tickeron's Trending AI Robots page.
Opening Summary
Twist Bioscience Corporation (TWST), a synthetic biology company that manufactures synthetic DNA on a proprietary silicon-based platform, saw its shares plunge roughly 15.22% on Thursday. The stock traded near $103.93, down from a prior-session close of $122.59. The selloff came after the company reported better-than-expected fiscal fourth-quarter results but issued fiscal 2027 guidance that fell short of the lofty expectations embedded in a stock that had more than quadrupled over the trailing year.
Earnings Beat, Guidance Disappoints
The immediate catalyst for the move was Twist Bioscience's fiscal 2026 fourth-quarter earnings release. The company posted revenue of $126.6 million, up 28% year over year and above the roughly $123.5 million analysts had projected, while its loss of $0.32 per share beat the consensus estimate for a loss of $0.38 per share. Full-year revenue reached a record $459.4 million, up 22%.
Despite the headline beat, the market reaction turned sharply negative on the company's forward outlook. Management guided fiscal 2027 revenue to a range of $550 million to $560 million, implying organic growth in the low-20% range. While that figure technically exceeded the consensus of roughly $549 million, it underwhelmed investors who had been pricing in stronger momentum, particularly given management's earlier commentary about "triple-digit" growth in its AI drug discovery business.
AI and Margin Expectations Reset
A key point of disappointment was the company's fiscal 2027 gross margin guidance of 52.5% to 53%, which trailed some analyst estimates and raised questions about the profitability profile of Twist's emerging AI drug discovery efforts. The outlook implied roughly $100 million in AI drug discovery revenue, or about 69% growth, well below the triple-digit trajectory previously signaled. Excluding AI drug discovery, analysts noted the guidance implied base-business growth of only around 14%, suggesting a broader slowdown.
Stretched Valuation and Short-Seller Pressure
The sharp decline also reflects the stock's extended positioning heading into the report. TWST had rallied dramatically in 2026, leaving its valuation at a premium relative to both its own history and peers. A critical report from The Bear Cave/Hunterbrook the prior week argued the stock traded at a premium unsupported by fundamentals, and elevated short interest of roughly 16% combined with notable insider selling had already dampened sentiment. Against that backdrop, guidance that failed to clear a high bar triggered profit-taking and selling pressure.
Market Context and Trading Activity
The move did not occur in a vacuum. Growth-oriented, high-beta names were broadly under pressure, with the Nasdaq down about 0.9% and the S&P 500 lower on the session. Twist's beta, estimated well above 2, made it particularly vulnerable to a risk-off tilt. Volume was elevated relative to typical levels as the earnings-driven revaluation unfolded, and the stock broke below key short-term technical levels, including its 50-day moving average, as momentum investors de-risked positions across the genomics and life-science tools complex.
What Comes Next for TWST
Investors will be watching how Wall Street recalibrates estimates and price targets following the guidance reset, as well as management's commentary on the trajectory of AI drug discovery bookings and margins in the coming quarters. The company's ability to translate its revenue growth into sustained profitability, particularly adjusted EBITDA expansion, remains a central focus. Risks include continued valuation pressure, the potential for further insider selling, and sensitivity to broader shifts in risk appetite across high-growth technology and healthcare equities. Upcoming quarterly updates and any developments in the AI-driven drug discovery pipeline will be closely monitored.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots designed to navigate changing market conditions. Tickeron offers hundreds of bots covering thousands of tickers, but only the strongest performers under current conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a range of approaches to consider. Explore the Trending AI Robots page to find strategies aligned with your trading objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
TWST's Stochastic Oscillator is sitting in oversold zone for 6 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +12.21% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 65 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 40 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.498). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement